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The  cells from plasmacytomas  induced  in  BALB/c and  susceptible BALB/c 
congenic strains of mice by pristane (2,6,10,14-tetramethylpentadecane)  (1) have 
non-random  chromosomal  translocations,  rcpt  (6;15) or rcpt(12;15)  (2,  3).  To 
date, the karyotypes of 27 early transfer generation or primary pristine-induced 
plasmacytomas have determined, and 26 of the tumors have either rcpt(6; 15) or 
rcpt(12;15)  (3-5).  The  transiocation  breakpoints  on these chromosomes occur 
in  the same chromosome bands  in all the plasmacytomas studied to date.  The 
breakpoints in chromosomes  12 and  15 have been studied by cloning and DNA 
sequencing.  The breakpoint  in chromosome  12 occurs in the immunoglobulin 
heavy chain gene (IgH) ~  complex, frequently, but not always, in the switch region 
of the alpha heavy chain gene (6-11).  In chromosome  15 the breakpoint occurs 
close to or within the c-myc oncogene (8-12). The breakpoints in chromosome 6 
have not yet been determined. Expression of c-myc RNA, often in relatively large 
amounts, characterized most of the plasmacytomas (11,  13,  14), and rearrange- 
ment of c-myc DNA was frequently seen. 
The development of plasma cell tumors in BALB/c mice injected with pristane 
alone  requires  a  minimum  of  120  d,  but  usually  more  than  200  d  (15).  In 
contrast,  plasmacytomagenesis  can  be  greatly  accelerated  (5,  16)  by infecting 
pristane-injected  mice  with  Abelson  virus.  This  murine  acute  leukemia  virus 
contains  two  retroviral  elements,  a  replication  competent  Moloney  leukemia 
virus helper and a  defective component,  A-MuLV (17).  The defective element 
has lost part or all of the viral gag, pol, and env genes and has acquired sequences 
from the mouse c-abl gene (for review see reference  18).  Adult mice of only a 
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few inbred  strains,  including BALB/c, are  susceptible  to  tumor  induction by 
Abelson virus. They generally develop pre-B cell lymphosarcomas (16,  17,  19, 
20) that appear 3-4 wk after infection with the virus. Although most of the mice 
developed lymphosarcomas, 5-25%  of the mice developed plasmacytomas (16). 
Unlike the plasmacytomas that arose 5 or more months after injection of pristane 
alone, the plasmacytomas induced in the presence of Abelson virus arose after 
relatively short latent periods (4-15 wk when determined from the time pristane 
was injected, or 3-9 wk when the latent period was determined from the time 
virus was injected). 
Whereas  pristane-induced  plasmacytomas  characteristically  contained  chro- 
mosome translocations, it has been previously shown that the lymphosarcomas 
induced  by  Abelson  virus  had  normal  karyotypes (21).  Further,  it  had  been 
shown that certain types of tumors induced by Abelson virus lack integrated v- 
abl sequences and v-abl transcripts (22, 23). Thus, investigation of the mechanism 
of carcinogenesis  in  plasmacytomas  induced  by  pristane  plus  Abelson  virus 
(ABPC) prompted an examination of the chromosomes of 18 transplanted ABPC 
for  evidence  of  translocations  of chromosome  15.  In  addition,  appropriate 
molecular hybridization studies were used to determine whether c-myc and v-abl 
sequences were being actively transcribed in these tumors. 
Materials and Methods 
Plasmacytomas, Abelson Virus.  The BALB/c plasmacytomas were induced in BALB/ 
can or BALB/c ~r female mice, by first injecting 0.5 ml pristane (2,6,10,14-tetramethyl- 
pentadecane, Aldrich Chemical Co., Milwaukee, WI 53233)  intraperitoneally (i.p.) fol- 
lowed 23-56  d  later by 0.1  ml of an Abelson virus preparation. Our stock of Abelson 
virus was originally obtained from Dr. Wallace P. Rowe, NIAID (16). New preparations 
of virus were prepared from the transplantable Abelson virus-induced lymphosarcoma 
ABLS 19.  10% (wt/vol) extracts of subcutaneous ABLS 19 tumor tissue contained ~ 106 
plaque-forming[  units/ml of viral activity (as measured in the XC test). Such preparations 
contained ~ 10 ~ lymphosarcoma-inducing units/ml. The tumors (listed in Table I) in the 
present study were derived from several different experiments carried out over the last 
10 years and were examined after transplatation. 
Detection of v-abl and c-myc.  Standard methods were used to prepare high molecular 
weight DNA (13,  24) and total RNA (25) from solid tissue excised from subcutaneous or 
intraperitoneal tumors.  The  presence  of absence  of an  integrated  A-MuLV proviral 
genome in the cellular DNA of a  tumor was determined by hybridization of Southern 
blots of nuclear DNA after digestion with Kpn I, which cleaves A-MuLV only in the LTR 
(26).  25 #g of DNA was fragmented by Kpn I endonuclease, electrophoresed in 0.7% 
agarose gels, and transferred to nitrocellulose paper. A subcloned 1.2-kbp abl-containing 
Bgl II fragment of cloned A-MuLV (26) was labeled with s~p by nick-translation (27) and 
hybridized with the tumor DNA. The presence of an intensely hybridized band at 6.7 
kbp indicated that A-MuLV had been integrated into the genome as a provirus. Electro- 
phoresis of 5 ~g ofpoly(A)  ÷ RNAs on 1% agarose gels containing 5 mM methyl mercury 
hydroxide, transfer to diazotized paper, and hybridization to the 32P-labeled v-abl probe 
described above were performed as presented elsewhere (13).  A-MuLV RNA appeared 
as an intensely hybridizing band of 6.6-kb RNA, while c-abl RNA transcripts took the 
form of 5.8-kb bands. 
Hybridization of blots of RNA and EcoRI digested DNA was also performed using a 
s2P-labeled mouse c-myc probe. This probe was a 5.5-kbp BamHI fragment that had been 
isolated from a  bacteriophage  library constructed  from the  plasmacytoma S107  and 
subcloned into pBR322 (28). 
Chromosome Analysis.  Metaphase spreads were performed from ascitic plasmacytomas 1764  CHROMOSOMES  AND  ONCOGENES  IN  ABELSON  PLASMACYTOMAS 
TABLE  I 
Characteristics of A-MuLV-Plus-Pristane-induced Plasmacytomas 
No. of day tu-  v-abl  Rear- 
mor arose  Heavy  ranged 
Tumor  After  After  chain  EcoRI myc  myc  RNA 
A-  pris-  class  DNA  RNA  DNA frag- 
MuLV  tane  ment 
Chromo- 
some trans- 
location 
rcpt 
ABPC  4  ?  ?  a  +  +  -  ++  6;  15 
17  58  99  a  +  +  +  ++  6; 15 
18  62  101  3'2b  +  +  +  ++*  12; 15 
20  21  78  72b  +  +  -  ++  6; 15 
22  52  98  #  +  +  -  ++  None 
24  32  88  a  +  +  +  ++*  12; 15 
26  ?  ?  a  +  +  -  ++  None* 
33  55  111  a  +  +  +  ++  12; 15 
45  46  69  a  +  +  +  ++  None* 
47  42  78  a  +  +  -  ++  12; 15 
48  28  84  a  +  +  +  ++  12;  15 
52  45  72  a  +  +  -  ++  12; 15 
60  62  98  3'1  +  +  -  ++  12;  15 
65  32  72  ND!  +  +  ND  ++  12; 15 
72  39  76  a  +  +  +  ++*  12; 15 
89  29  49  a  +  +  -  ++  12; 15 
103 m  32  88  "rl  +  +  -  ++  6;  15 
105  72  102  a  +  +  -  ++  6; 15 
* Shortened myc RNA present. 
* Internal deletion within chromosome 15 can be detected by high resolution banding (39). 
| ND, not determined. 
I The ABPC 103 was derived from an experiment done in collaboration with Dr. Charles D. Scher, 
Sidney Farber Cancer Institute, Boston, MA.  It originated from spleen cells from the BALB/c 
C.B20 congenic mouse. This mouse was injected with pristane on day 0, and 40 d later spleen cells 
were cultured in RPMI 1640 medium containing BALB/c cells, 5 x 10  -5 M mercaptoethanol, and 
50 tzg/ml lipopolysaccharide. The spleen cells were incubated with Abelson virus stock NIH/PCV- 
6  22/MLV-C with a titer of 8 x  10  FFU/ml and 1.5 X 10  PFU/ml and 2 #g/ml polybrene for 2 h 
before culture. 9 d later 1.6 x  106 cells were injected into each of 82 BALB/c mice that had been 
conditioned with 0.5 ml pristane 30 d before. One BALB]c recipient developed a plasmacytoma 
30 d later. Upon transplantation it was shown that the tumor, designated ABPC 103, secreted an 
IgG~ myeloma protein of C.B20 origin. This datum suggested that ABPC  103  arose in a  C.B20 
lipopolysaccharide blast spleen cell in vitro. 
without colcemid treatment. Banded metaphase plates were prepared by using a  slightly 
modified method of Wang and Federoff (29). High quality promethaphase and prophase 
chromosome plates were prepared according to the method of Yu et al. (30), adapted to 
mouse chromosomes. Chromosome identification followed the recommendations of the 
Committee on Standard Genetic Nomenclature for Mice (31). Breakpoints of translocated 
chromosomes were located according to Nesbitt and Francke (32). 
Results 
The  18  plasmacytomas  utilized  in  the  present  study were  taken  at  random 
from a  series of 60 that had been induced in BALB/c mice that had first been 
given a  single  0.5  ml i.p.  injection  of pristane,  followed by an i.p.  injection  of 
Abelson virus 20-60 d  later (usually 40-50  d  after pristane).  The mean  latent 
period of these 60 plasmacytomas was 89 d (range 49-149 d). The latent period 
determined from the time of virus injection was 43 d (range 21-93 d). The mean OHNO  ET  AL.  1765 
latent period of 77 plasmacytomas induced in BALB/c mice by a single injection 
of 0.5  ml pristane alone was 221  d  (range  140-360  d).  A  comparison of the 
latent periods is shown graphically in Fig.  1, and the individual latent periods of 
the tumors used in this study are presented in Table I. 
Hybridization Studies.  As summarized in Table I, A-MuLV RNA was detected 
as a 6.6-kb v-abl hybridizing RNA in all the ABPC. Similarly, A-MuLV provirus 
was detected in Kpn I digested DNA from all ABPC as a 6.7-kbp abt hybridizing 
band.  Fig.  2  shows representative examples of abl-hybridized  RNA and DNA 
blots of ABPC, normal tissues, and ABPL 1, a iymphosarcoma tumor that arose 
after Abelson virus-plus-pristane injection but, which contains neither RNA nor 
DNA from A-MuLV (22). The only ABPC tumor without the 6.7-kbp abl proviral 
Kpn  fragment  is  ABPC  60,  which  has  a  smaller,  5.8-kb,  v-abl  RNA  and  a 
correspondingly smaller, 5.9-kbp, proviral DNA fragment. 
Hybridization with the c-myc gene probe revealed that 7 ABPC (ABPC 17, 18, 
24,  33,  45,  48,  and  72) showed altered EcoRI myc  fragments, indicating that 
rearrangements had occurred at the myc gene locus. Three of these seven tumors 
(ABPC  18, 24, and 72) contained 1.8-kb myc RNA indicating that some of the 
rearranged myc genes gave rise to altered mRNA transcripts. These results are 
summarized in Table I, and representative examples of myc-hybridized RNA and 
DNA blots of ABPC and normal tissues are shown in Fig.  3.  The altered (1.8 
kb) myc RNA has been found so far only in tumors with rcpt(12; 15) translocations. 
It is important to note that rearrangements at the myc gene locus could be seen 
in one tumor with no translocation (ABPC 45) as well as in one tumor containing 
rcpt(6;15) (ABPC 17) (Table I). 
Karyotypes.  The karyotypes of 18 ABPC are summarized in Table II. ABPC 
4, 17, 47, 48, and 72 had near-tetraploid chromosome constitutions, while ABPC 
20 and ABPC 33 showed near-diploid populations. The other 11 ABPC (ABPC 
18, 22, 24, 26, 45, 52, 60, 65, 89,  103, and 105) had both near-diploid cells and 
near-tetraploid  cells.  In  spite  of this  wide  variation  in  chromosome number, 
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FIGURE  1.  Comparison  of the  latent  periods  of 77  plasmacytomas  induced  with  0.5  ml 
pristane with  18 plasmacytomas induced with 0.5 ml pristane plus A-MuLV. The A-MuLV- 
associated plasmacytomas appeared on an average of 80 d before plasmacytomas induced with 
pristane  alone.  (0)  percent of tumors  induced  with  A-MuLV plus pristane,  (O) percent of 
tumors induced with pristane alone. 1766  CHROMOSOMES  AND  ONCOGENES  IN  ABELSON  PLASMACYTOMAS 
FIGURE 2.  RNA and DNA blots hybridized with v-abl.  (a) 5 #g poly(A)  ÷ RNA from tumors 
and tissues indicated were separated by electrophoresis on 1% agarose gels containing 5 mM 
methyl mercury hydroxide. After blotting onto diazotized paper, the RNAs were hybridized 
(13) with a  v-abl probe and exposed to film. Typical A-MuLV RNA of 6.6 kb was abundant 
in all ABPC's except ABPC 60, which contained a presumed deletional mutant of A-MuLV. 
Faint bands of c-abl RNA transcripts of 5.6 kb can also be seen in some ABPC tumors. Similar 
c-abl  RNAs can be seen in tumors such as ABPL  1 that lack v-abl expression and in normal 
thymus after longer exposures. (b) 2.5 #g of DNA from the tumors and tissue indicated were 
digested to completion with Kpn I, electrophoretically separated on 0.7% agarose and blotted 
onto nitrocellulose.  The  blot was hybridized with a  v-abl probe (13) and exposed  to film. 
Normal liver and ABPL 1 DNA showed 2 hybridizing bands of 8.3 and 24 kbp. All ABPC's 
showed one additional hybridizing band of 6.7 kbp, except ABPC 60 which demonstrated the 
two normal bands and one additional band of .5.9 kbp. The additional band is presumed to be 
the A-MuLV provirus, which has undergone a deletional mutation in ABPC 60. 
FIGURE 3.  DNA and RNA blots hybridzed with c-myc. (a) Southern blots of 25 #g of DNA 
from the tumors and tissue indicated processed as in Fig. 2 b and hybridized with c-myc probe. 
Most tumors and the normal liver have a single hybridizing band at ~21 kbp, but some ABPC's 
have an additional smaller hybridizing band at ~ 14 kbp. (b) Blot of 5 #g poly(A)  + RNA from 
tumors and tissues indicated processed as in Fig.  2 a  and hybridizing with c-myc probe. Most 
tumors have a  broad,  intensely hybridizing band of RNA of ~2.4  kb.  Normal  tissues also 
contain myc RNA of this size, but normal tissues have less of this rayc RNA than most ABPC's. 
Some ABPC's also have a myc RNA band of ~1.8 kb which is not found in normal tissues. OHNO ET  AL.  1767 
banding analysis revealed a  remarkable uniformity in chromosome aberrations, 
specifically  the  non-random  reciprocal  translocation  involving one  of the  Ig 
gene-bearing chromosomes 6 or 12 and chromosome 15. Of 18 ABPC analyzed, 
5/18 showed rcpt(6;15) (ABPC 4,  17, 20,  103, and 105) (Fig. 4) and 10/18 had 
rcpt(12;15) (ABPC 18, 24, 33, 47, 48, 52, 60, 65, 72, and 89) translocation (see 
Fig. 6). Specific breakpoints associated with these translocations were at  15D2/ 
3, 6C2, and 12F2, respectively. It should be noted that three ABPC (ABPC 22, 
26, and 45) had no chromosome translocations. 
In 7 of the 11 tumors with both tetraploid and diploid chromosome numbers, 
ABPC  18,  24,  45,  60,  65,  89, and  103, the diploid cells far outnumbered the 
near-tetraploid cells (Table  II).  In tumors showing 41  chromosomes the addi- 
tional chromosome was usually chromosome  11.  Trisomy  11  occurred in cells 
from  2/5  tumors  with  rcpt(6;15)  (ABPC  103  and  105),  6/10  tumors  with 
rcpt(12;15)  (ABPC  18,  24,  33,  60,  65,  and  89),  and  all  3  tumors  with  no 
translocations (ABPC 22, 26, and 45) (Fig. 5). 
A  few plates of 41  or 42  chromosomes were equivocal for the presence of 
trisomy 11. This was due to the inability to identify each chromosome in certain 
preparations with poor G-banding quality, rather than the absence of the trisomy 
11. 
A variety of other structural aberrations was also present in occasional tumors. 
The  trisomy  .11  in  ABPC  60  was  due  to  a  single  No.  11  and  a  copy  of 
isochromosome of No.  11  [Rb(11;11)].  ABPC24 showed 1 to 2 copies of a long 
chromosome, possibly resulting from a  single translocadon of chromosome 18 
onto the telomeric end of chromosome X  (terminal addition). The isochromo- 
some of No. 6 [Rb(6;6)] was identified in ABPC 47. Of 16 plates analyzed from 
this  tumor,  10  cells  were  positive  for  Rb(6;6)  while  the  others  (6/16)  were 
negative.  Finally,  a  number  of metaphase  plates  with  39  chromosomes were 
found in ABPC 52.  Karyotype analysis revealed that a  copy of chromosome X 
has been deleted (Fig. 6). 
Discussion 
A  striking feature of pristane-induced plasmacytomas in BALB/c mice is the 
occurrence of the reciprocal translocations rcpt(6; 15), rcpt(12; 15) (references 2- 
5) or interstitial deletions of chromosome  15  (del  15qDlqE)  (references 2,  3). 
One of these three chromosome-15 abnormalities has been found in all pristane- 
induced plasmacytomas so far studied (2, 5). The breaksite in chromosome 15 
in all of the tumors examined occurs within or near the c-myc oncogene (8,  11, 
12, 14) and is associated with myc gene transcription (9, 13, 14), often in relatively 
large amounts. Similar forms of chromosomal abnormalities involving the myc 
gene chromosome-8 in man (33) and chromosome-7 in the rat (34) have been 
found. The importance of myc gene activation by retroviral promoter insertion 
has been demonstrated in Bursal lymphomatosis in the chicken (35, 36). It would 
appear  that  myc  gene  activation  is  a  critical  event  in  many  forms  of B  cell 
neoplasia; however, it is not clear that it is the only oncogenic event. 
In the present study we have examined another experimental form of plas- 
macytomagenesis in BALB/c mice, the short-latent period plasmacytomas that 
are  induced by infecting pristane-treated  mice with Abelson virus.  The mean 1768  CHROMOSOMES  AND  ONCOGENES  IN  ABELSON  PLASMACYTOMAS 
TABLE II 
Karyotype and Protein Analysis of A-MuL  V-Plus-Pristane-induced Plasmacytomas with Near- 
diploid and Near-tetraploid Chromosome Constitution 
No. of 
Trans-  Chromosome con-  meta-  Trisomy 11 
Plasmacy-  plant  Mye-  stitution (no. of  phase  Type of chromo-  (no. of plates] 
loma  total no. of  plates/total no. of  plates  some aberration  toma  genera-  protein  plates ana- 
tion  plates analyzed)  ana- 
lyzed  lyzed) 
ABPC  4  18  IgA, K  65 (Range: 44-68)  26  rcpt (6;  15),*  .~ 
6q--, 15q+ 
ABPC  17  14  IgA, ~  65 (Range: 45-68)  26  rcpt (6; 15),  ? 
6q-, 15q+ 
ABPC  18  4  lgG2b, K  41 (8]29)  29  rcpt (12; 15),  0  41 (8]8) 
42 (19/29)  12q+, 15q-  42 (16/19) 
83 (1/29) 
85 (1/29) 
ABPC  20  9  IgG~b,  K  40 (7/10)  10  rcpt (6;  15),  No trisomy 11 
41 (2]10)  6q-, 15q+ 
42 (1]10) 
ABPC  22  I 1  IgM, ~  41 (3/26)  26  No transloca-  41 (3/3) 
42 (9/26)  tions  42 (9/9) 
43 (1/26)  43 (1/1) 
81 (Range: 60-85) 
(13/26) 
ABPC  24  8  IgA, K  39 (1/24)  24  rcpt (12; 15),  39 (1/1) 
40 (3]24)  12q+, 15q-, 
41 (12/24)  Xq+  41 (11/12) 
42 (5/24)  42 (5/5) 
78-85 (3/24) 
ABPC  26  5  IgA  40 (3/20)  20  No transloca-  41 (4•5) 
41 (5/20)  tions  ! 
76 (Range: 71-81) 
(12]20) 
ABPC  33  16  IgA, K  38 (1/9)  9  rcpt (12; 15),  38 (1]1) 
40 (2/9)  12q+,  15q- 
41 (6/9)  41 (6]6) 
ABPC  45  7  IgA, K  40 (4/25)  25  No transloca- 
41 (11/25)  tions  I  41 (8/11) 
80 (Range: 56-82) 
(10/25) 
ABPC  47  20  IgA, K  85 (Range: 77-85)  16  rcpt (12; 15),  ? 
12q+, 15q-, 
Rb (6; 6)  ~ 
ABPC  48  11  IgA, x  78 (Range: 54-81)  14  rcpt (12; 15),  ? 
12q+, 15q- 
ABPC  52  15  IgA, x  39 (13/19)  19  rcpt (12; 15),  No trisomy 11 
79 (Range: 64-80)  12q+, 15q- 
(6/19) 
40 (1/14) 
41 (10/14) 
65-82 (3/14) 
ABPC  60  7  IgG]  14  rcpt (12; 15), 
12q+, 15q-, 
Rb(ll;ll)** 
41 (10/10) OHNO  ET  AL. 
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No. of 
Trans-  Chromosome con-  meta-  Trisomy 11 
Mye-  stitution (no. of  phase  Type of chromo-  (no.  of plates/  Plasmacy-  plant  loma  total no. of 
plates/total no. of  plates  some aberration  toma  genera-  protein  plates ana- 
tion  plates analyzed)  ana-  lyzed) 
lyzed 
ABPC  65  7  ND  ~  40 (7/17)  17  rcpt (12; t5), 
41 (7/17)  12q+,  15q-  41 (7/17) 
74 (1/17)  2 plates: RB 
80 (1/17)  (ll; ll) 
82 (1/17) 
ABPC  72  8  IgA  76 (Range: 65-80)  14  rcpt (12; 15)  ? 
12q+, 15q- 
ABPC  89  7  IgA  40 (1/2I)  21  rcpt (12; 15), 
41 (18/21)  12q+, 15q-  41 (17/18) 
79 (1/21) 
81 (1/21) 
ABPC  103  2  IgGl, K  40 (12/31)  31  rcpt (6; 15) 
41 (14/31)  6q-, 15q+  41 (13/14) 
80 (Range: 47-83) 
(5/31) 
ABPC  105  2  IgA, r  40 (1/24)  24  rcpt (6; 15), 
41 (3/24)  6q-, 15q+  41 (2/3) 
42 (1/24)  42 (1/1) 
78 (Range: 54-80) 
(19/24) 
* Reciprocal translocation between chromosomes 6 and 15. 
* The metaphase plastes were potyploid. Therefore, in these plasmacytomas it was not possible to 
define which chromosome was specifically duplicated first. 
Reciprocal translocation between chromosomes 12 and 15: 
! The possible deletion  of D1  and D2 regions on chromosome  15 in the translocation-negative 
plasmacytomas (ABPC 22, 26, and 45) has been found by the high resolution banding technique. 
Robertsonian translocation between two chromosomes 6. 
** Robertsonian translocation between two chromosomes 1  I. 
** Not determined. 
latent period for plasmacytoma development following a  single injection of 0.5 
ml pristane alone is 221  d  (range  140 to 360 d).  Introducing A-MuLV 20 to 40 
d  after an i.p.  injection of 0.5 ml pristane reduces the mean latent period to 89 
d  (range 49 to  149 d  determined from the time of the pristane injection). 
Abelson  virus alone  has  not  yet  been  observed  to  induce  plasmacytomas in 
normal  BALB/c  mice  (16).  Rather,  plasmacytoma induction  requires  the  for- 
mation  of  a  pathological  peritoneal  granulomatous  tissue  by  such  agents  as 
mineral oils, pristane,  or solid plastics.  This tissue is important for the develop- 
ment  (37)  and  maintenance  (38)  of the  primary  plasmacytomas.  The  chronic 
inflammatory tissue in the peritoneum  may be an essential factor in generating 
cells with  chromosome  15  translocations;  however,  this has not  yet been  dem- 
onstrated. 
The karyotypes of ABPC were of particular interest because of the possibility 
that  the  A-MuLV  transduction  of v-abl sequences  into  the  genomes of plasma 
cells would be sufficient to transform the  cells.  We found,  however, the  nearly 
universal presence of another  genetic alteration,  i.e.,  15  of the  18  tumors had 1770  CHROMOSOMES AND  ONCOGENES IN  ABELSON PLASMACYTOMAS 
FIGURE  4.  G-banded karyotype of a diploid plasmacytoma cell (ABPC 103, generation 2). 
Note the presence of one copy of rcpt(6; 15) representing 6q- and 15q+. 
translocations of chromosome 15, and 2 had interstitial deletions of chromosome 
15  (Table  I,  reference  39).  Only  one  tumor  (ABPC  22)  lacked  a  detectable 
chromosome  15  anomaly (39).  All  of the  ABPC  actively transcribed  myc  gene 
sequences. 
Hybridization studies revealed that all of the ABPC transcribe large amounts 
of v-abl and contain stable inserts of v-abl in their chromosomes (Fig. 2). Abelson 
virus has been associated with the induction of neoplasms that have lost both the OHNO  ET  AL.  1771 
FIGURE 5.  G-banded karyotype of a near-diploid plasmacytoma cell (ABPC 22, generation 
11). Neither  rcpt(6;15) nor rcpt(12;15). Not the presence of trisomy 11. Trisomy  10 and 
monosomy 16 are also seen. However, the latter two changes occur in a random manner and 
without any consistency  between different tumors. 
virus  and  the  v-abl  inserts  (22,  23).  In  Abelson  virus-induced  plasmacytoid 
lymphosarcomas that  appear  to have  lost v-abl,  other  oncogenes are  activated 
and rearranged,  notably the myb oncogene. The stability of the v-abl inserts in 
the ABPC form of tumor provides strong evidence that v-abl plays an important 
role in maintaining the neoplastic state in these plasmacytomas.  Further, it may 
be reasonable to consider that myc gene activation and v-abl transduction coop- 
erate in completing the neoplastic transformation of plasma cells. 1772  CHROMOSOMES  AND  ONCOGENES  IN  ABELSON  PLASMACYTOMAS 
FIGURE 6.  G-banded  karyotype of a  hypodiploid plasmacytoma cell (ABPC 52, generation 
15).  Note  the  presence  of  one  copy  of  rcpt(12;15)  representing  12q+  and  15q-.  One 
chromosome X is deleted. 
It is tempting to speculate that in these tumors there is a sequential pattern of 
expression  of these  oncogenes  with  myc  gene  activation  by  chromosome-15 
alteration occurring first, to be followed by v-abl transduction. Several facts lead 
us  to  propose  this  hypothesis.  First,  chromosomal translocations probably are 
incurred during differentiation of the Ig genes, that is,  in pre-B lymphocytes. OHNO ET AL.  1773 
Identical forms of myc chromosome translocations occur in Burkitt's lymphoma 
and other pre-B cell tumors in man (11,  33,  40) and immunocytomas in rats 
(34).  Thus, these translocations can occur at the pre-B cell stage in mammals. 
The effect of chromosomal translocation with its associated myc gene activation 
on pre-B cell physiology is not known; alone it may not be sufficient to transform 
the lymphocytes to a  neoplastic state.  A  second mutational  event is  probably 
required. Since this would most likely occur by chance, it would entail a  long 
latent period, such as that known for plasmacytoma development in mice injected 
with  pristane  or  mineral  oil  alone.  Transduction  of v-abl  by  Abelson  virus 
apparently can also fulfill this second event function. In Burkitt's lymphoma and 
"pristane-only"  plasmacytomagenesis, a  second  oncogene probably  also  is  in- 
volved but as yet has not been conclusively identified. Transforming genes (other 
than myc) have been isolated from plasmacytomas and Burkitt's lymphomas (41, 
42), e.g., B-lym (43), and these may represent such a second gene. Further c-mos 
has been found to be activated in some plasmacytomas (44), but it is unlikely that 
c-mos alteration represents a commonly used second event in neoplasia. 
Recently it has been proposed that in DNA viral oncogenesis (polyoma, SV40, 
adenoviruses) early function genes, e.g., E1A from adenovirus and large T  from 
polyoma have properties similar to the myc gene (45-47). The protein products 
of all these genes, like myc (48-50), are located in the nuclear matrix and bind 
DNA (49).Further, in transforming experiments involving transfection with myc 
gene sequences, the myc gene alone is not able to transform cells to full neoplasia 
by itself (45),  whereas it,  as well as  E1A,  can cooperate with  ras  in  inducing 
transformation. It is thought, though, that in in vitro systems the myc oncogene 
plays an important role in the continuous establishment of the cell lines (45, 46). 
The in vivo counterpart of myc gene function may be to keep cells that have been 
triggered for immunoglobulin secretion in continuous mitosis, thus blocking the 
normal mechanism of cell elimination via terminal differentiation and creating 
an anomalous cell. The second oncogenic event may then lock the proliferative 
activity of these cells into a state where they can no longer be regulated in vivo. 
There were several points of interest in the karyological studies of the ABPC. 
The distribution of the two types of translocations was different, e.g., the number 
of tumors with rcpt(6;15)  is higher (22%)  than the pristane-only group  (7%). 
Further,  there were many more near-diploid chromosome numbers in  ABPC 
cells than in tumors produced by pristane alone. The high frequency of near- 
diploid  cells  made it  possible  to  show that  trisomy of chromosome  11  was  a 
potentially important abnormality. Trisomy 11 was found in 11 of the 14 tumors 
in which diploid cells were present. It is of interest to note that ABPC 22,  26, 
and 45  had the trisomy 11  in the absence of the usual translocations found in 
plasmacytomas. It is unlikely that the trisomy 11  supplants or substitutes for a 
rearrangement of the  myc  locus  in  chromosome  15  in  the  3  ABPC  lacking 
chromosome-15 translocation, because in a few tumors, e.g., ABPC 65, only half 
of the diploid cells had trisomy 11, and in other tumors we found some purely 
diploid metaphase plates (40 chromosomes) that showed rcpt(6;15) (ABPC 103, 
105) or rcpt(12;15) (ABPC 24, 33, 60, 65, 89) without trisomy 11. The signifi- 
cance of the trisomy 11 in plasmacytomagenesis is not known, but it is of interest 
that the gene encoding the P53 transformation-associated protein is located on 1774  CHROMOSOMES  AND ONCOGENES IN  ABELSON PLASMACYTOMAS 
chromosome  11  (51).  Thus,  trisomy  11  may amplify the amounts of this  gene 
product. 
Rcpt(12;15)  was  consistently  present  in  plates  with  39  chromosomes  from 
which one copy of chromosome X was deleted. Additional chromosome aberra- 
tions  such  as  Rb(ll;ll),  Rb(6;6),  deletion  of one  chromosome  X,  possible 
translocation between chromosomes 18 and X, and trisomies of No. 3, 6, or 10 
were also observed. They occurred in an apparently random manner and without 
any  consistency  between  different  tumors.  It  is,  therefore,  likely  that  they 
represent secondary changes. 
Summary 
Plasmacytomas with short latent periods can be induced in BALB/c mice by a 
single intraperitoneal  (i.p.) injection  of 0.5  ml pristane  followed 20-40 d  later 
by  an  injection  of Abelson  virus.  The  karyotypes  of  18  such  tumors  were 
determined;  10 of these had rcpt  12;15, 5 had rcpt 6;15 and 3 had no translo- 
cations,  but  two  of  these  have  been  shown  to  have  interstitial  deletions  of 
chromosome 15. The specific breakpoints were the same as described in pristane- 
induced plasmacytomas, i.e., at 15D2/3, 6C2, and 12F2. Near diploid karyotypes 
and trisomy of chromosome  11  were frequently seen. All of the Abelson-plus- 
pristane-induced  plasmacytomas (ABPC) were studied as transplanted  tumors, 
contained integrated v-abl sequences, and actively transcribed v-abl mRNA. All 
but one of these tumors contained abundant myc RNA transcripts. The shortness 
of the  latent  periods of the ABPC suggests that  the rcpt  12;15 and  rcpt  6;15 
occur soon after pristane  administration  and  are present  at  the  time  Abelson 
virus is introduced.  In  this form of plasmacytomagenesis, activated v-abl genes 
appear  to bypass other genetic changes  that  require  a  much  longer  period  of 
time  in  pristane  plasmacytomagenesis.  Nonetheless,  the  consistent  finding  of 
chromosome-15 alterations and abundant myc expression in these plasmacytomas 
emphasize  the apparent  need  for multiple  events even  in  the  genesis of some 
tumors induced by rapid transforming viruses. 
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